Federal Register / Vol. 80, No. 15 / Friday, January 23, 2015 / Notices 3607 

Desk Officer for the Administration for 

Children and Families. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2015–01122 Filed 1–22–15; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

[CFDA Number 93.645] 

Correction to the Notice of Allotment 

Percentages to States for Child 

Welfare Services State Grants 

AGENCY: Administration on Children, 

Youth and Families, Administration for 

Children and Families, Department of 

Health and Human Services. 

ACTION: Notice; correction. 

SUMMARY: The Administration on 

Children, Youth and Families, 

Administration on Children and 

Families published a document in the 

Federal Register of November 28, 2014, 

concerning the biennial publication of 

allotment percentages for States under 

Title IV–B subpart 1, Child Welfare 

Services State Grants Program. The 

document contained an incorrect 

allotment percentage for the District of 

Columbia. 

FOR FURTHER INFORMATION CONTACT: 

Deborah Bell, Grants Fiscal Management 

Specialist, Office of Grants 

Management, Office of Administration, 

Administration for Children and 

Families, telephone (202) 401–4611. 

Correction: In the Federal Register of 

November 28, 2014, in FR. Doc. 2014– 

28135, on page 70873, in the second 

column, correct the ‘‘Allotment 

Percentage’’ for the District of Columbia 

from ‘‘14.17’’ to ‘‘30.00.’’ 

Melody Wayland, 

Senior Grants Policy Specialist, Office of 

Administration. 

[FR Doc. 2015–01106 Filed 1–22–15; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2008–N–0312] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Extralabel Drug 

Use in Animals 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Fax written comments on the 

collection of information by February 

23, 2015. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–7285, or emailed to oira_

submission@omb.eop.gov. All 

comments should be identified with the 

OMB control number 0910–0325. Also 

include the FDA docket number found 

in brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: FDA 

PRA Staff, Office of Operations, Food 

and Drug Administration, 8455 

Colesville Road; COLE–14526, Silver 

Spring, MD 20993–0002, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Extralabel Drug Use in Animals—21 

CFR 530 (OMB Control Number—0910– 

0325)—(Extension) 

The Animal Medicinal Drug Use 

Clarification Act of 1994 allows a 

veterinarian to prescribe the extralabel 

use of approved new animal drugs. 

Also, it permits FDA, if it finds that 

there is a reasonable probability that the 

extralabel use of an animal drug may 

present a risk to the public health, to 

establish a safe level for a residue from 

the extralabel use of the drug, and to 

require the development of an analytical 

method for the detection of residues 

above that established safe level. 

Although to date we have not 

established a safe level for a residue 

from the extralabel use of any new 

animal drug and, therefore, have not 

required the development of analytical 

methodology, we believe that there may 

be instances when analytical 

methodology will be required. We are, 

therefore, estimating the reporting 

burden based on two methods being 

required annually. The requirement to 

establish an analytical method may be 

fulfilled by any interested person. We 

believe that the sponsor of the drug will 

be willing to develop the method in 

most cases. Alternatively, FDA, the 

sponsor, and perhaps a third party may 

cooperatively arrange for method 

development. The respondents may be 

sponsors of new animal drugs, State, or 

Federal and/or State Agencies, 

academia, or individuals. 

In the Federal Register of November 

4, 2014 (79 FR 65408), FDA published 

a 60-day notice requesting public 

comment on the proposed collection of 

information. No comments were 

received. 

FDA estimates the burden of this 

collection of information as follows: 

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1

21 CFR Section Number of 

respondents 

Number of 

responses per 

respondent 

Total annual 

responses 

Average 

burden per 

response 

Total hours 

530.22(b) .............................................................................. 2 1 2 4,160 8,320 

1There are no capital costs or operating and maintenance costs associated with this collection of information. 


tkelley on DSK3SPTVN1PROD with NOTICES